NovoCure Limited (NVCR) Operating Margin
- Operating margin · 12 months: Value -22.08%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -22.08% | Operating income / revenue. Period ending 2026-06-30. $-154.40M ÷ $699.19M × 100 ≈ -22.08% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -154.40M USD | Operating Income (Loss) |
| Revenue | 699.19M USD | |
| Cost of products and services | (m) | |
| Research and development | 224.72M USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-154.40M | $699.19M | (m) | $224.72M | (m) | -22.08% |
| 2026-03-31 | $-183.35M | $674.41M | (m) | $229.10M | (m) | -27.19% |
| 2025-12-31 | $-153.80M | $655.35M | (m) | $224.54M | (m) | -23.47% |
| 2025-09-30 | $-176.71M | $642.27M | (m) | $214.85M | (m) | -27.51% |
| 2025-06-30 | $-172.78M | $630.16M | (m) | $212.70M | (m) | -27.42% |
| 2025-03-31 | $-166.84M | $621.71M | (m) | $211.82M | (m) | -26.84% |
| 2024-12-31 | $-170.50M | $605.22M | (m) | $209.65M | (m) | -28.17% |
| 2024-09-30 | $-158.91M | $577.74M | (m) | $212.74M | (m) | -27.51% |
| 2024-06-30 | $-185.06M | $549.96M | (m) | $214.48M | (m) | -33.65% |
| 2024-03-31 | $-214.14M | $525.66M | (m) | $214.96M | (m) | -40.74% |
| 2023-12-31 | $-232.87M | $509.34M | (m) | $223.06M | (m) | -45.72% |
| 2023-09-30 | $-224.13M | $503.98M | (m) | $223.57M | (m) | -44.47% |
| 2023-06-30 | $-190.50M | $507.66M | (m) | $221.91M | (m) | -37.52% |
| 2023-03-31 | $-148.97M | $522.48M | (m) | $223.56M | (m) | -28.51% |
| 2022-12-31 | $-89.52M | $537.84M | (m) | $206.09M | (m) | -16.64% |
| 2022-09-30 | $-69.94M | $542.62M | (m) | $208.20M | (m) | -12.89% |
| 2022-06-30 | $-53.88M | $545.23M | (m) | $204.38M | (m) | -9.88% |
| 2022-03-31 | $-45.05M | $537.88M | (m) | $197.62M | (m) | -8.38% |
| 2021-12-31 | $-44.33M | $535.03M | (m) | $201.30M | (m) | -8.29% |
| 2021-09-30 | $-8.84M | $545.77M | (m) | $188.37M | (m) | -1.62% |
| 2021-06-30 | $14.73M | $544.83M | (m) | $173.05M | (m) | 2.70% |
| 2021-03-31 | $33.69M | $527.23M | (m) | $152.66M | (m) | 6.39% |
| 2020-12-31 | $30.40M | $494.37M | (m) | $132.01M | (m) | 6.15% |
| 2020-09-30 | $18.46M | $449.65M | (m) | $111.75M | (m) | 4.11% |
| 2020-06-30 | $7.29M | $409.05M | (m) | $97.70M | (m) | 1.78% |
| 2020-03-31 | $1.82M | $379.84M | (m) | $87.23M | (m) | 0.48% |
| 2019-12-31 | $-914.00K | $351.32M | (m) | $79.00M | (m) | -0.26% |
| 2019-09-30 | $-9.73M | $321.76M | (m) | $70.30M | (m) | -3.02% |
| 2019-06-30 | $-18.83M | $294.45M | (m) | $64.60M | (m) | -6.40% |
| 2019-03-31 | $-27.11M | $269.25M | (m) | $56.51M | (m) | -10.07% |
| 2018-12-31 | $-33.67M | $248.07M | (m) | $50.57M | (m) | -13.57% |
| 2018-09-30 | $-29.51M | $232.06M | (m) | $45.59M | (m) | -12.72% |
| 2018-06-30 | $-30.19M | $217.41M | (m) | $41.79M | (m) | -13.88% |
| 2018-03-31 | $-38.63M | $194.27M | (m) | $39.80M | (m) | -19.89% |
| 2017-12-31 | $-39.33M | $177.03M | (m) | $38.10M | (m) | -22.22% |
| 2017-09-30 | $-52.70M | $153.61M | (m) | $36.53M | (m) | -34.31% |
| 2017-06-30 | $-75.05M | $125.17M | (m) | $37.49M | (m) | -59.95% |
| 2017-03-31 | $-96.75M | $104.72M | (m) | $39.43M | (m) | -92.40% |
| 2016-12-31 | $-115.32M | $82.89M | (m) | $41.47M | (m) | -139.12% |
| 2016-09-30 | $-128.05M | $65.03M | (m) | $43.84M | (m) | -196.91% |
| 2016-06-30 | $-124.02M | $52.31M | (m) | $43.82M | (m) | -237.09% |
| 2016-03-31 | $-113.99M | $40.93M | (m) | $45.27M | (m) | -278.48% |
| 2015-12-31 | $-104.00M | $33.09M | (m) | $43.75M | (m) | -314.31% |
| 2015-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | $-80.16M | $15.49M | (m) | $40.38M | (m) | -517.47% |
| 2014-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | $-64.46M | $10.36M | (m) | $34.80M | (m) | -622.25% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEMAITRE VASCULAR INC (LMAT) | United States | $1.848B | 33.37 |
| Inspire Medical Systems, Inc. (INSP) | United States | $1.990B | 9.55 |
| KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) | United States | $1.535B | -9.02 |
| Alphatec Holdings, Inc. (ATEC) | United States | $1.531B | -12.14 |
| UFP TECHNOLOGIES INC (UFPT) | United States | $2.308B | 28.37 |
| INTEGRA LIFESCIENCES HOLDINGS CORP (IART) | United States | $1.234B | -193.02 |
| ARTIVION, INC. (AORT) | United States | $1.123B | -345.09 |
| IRADIMED CORP (IRMD) | United States | $1.089B | 52.92 |
| TANDEM DIABETES CARE INC (TNDM) | United States | $1.059B | -16.57 |
| PROCEPT BioRobotics Corp (PRCT) | United States | $1.001B | -11.77 |